Scientific Online Resource System

Scripta Scientifica Medica

Galectin-3 expression in thyroid tumors

Mira Siderova, Kiril Hristozov, Ivan Krasnaliev, Radoslav Radev, Rumen Nenkov

Abstract

Aim. To evaluate the expression of Galectin-3 in benign and malignant thyroid nodules and to assess its diagnostic value.

Methods. Immunohistochemical analysis of Galectin-3 expression was performed on 64 surgically removed thyroid nodules, including 38 carcinomas (13 papillary, 2 tall cell variants, 4 lymph node metastases from papillary carcinoma,6 follicular variants of papillary carcinoma (FVPTC), 4 anaplastic, 5 follicular and 4 Hürthle cell carcinomas), as well as 26 benign lesions (10 follicular adenomas, 5 Hürthle cell adenomas, 11 nodular goiters with surrounding normal thyroid tissue).

Results. We found strong and diffuse Galectin-3 expression in all malignant lesions except for one case of FVPTC and one follicular carcinoma. Normal thyrocytes and the majority of the benign lesions were negative for Galectin-3. This molecular marker was expressed in the cytoplasm as well as in the nuclei of follicular cells. Statistical analysis determined sensitivity 94.7%, specificity 69.2%, PPV 81.8%, NPV 90% and accuracy 83% of Galectin-3.

Conclusion. Our findings suggest that immunohistochemical expression of Galectin-3 might contribute to differential diagnosis between malignant and benign thyroid nodules, including those with follicular architecture.


Keywords

Galectin-3; immunohistochemistry; thyroid carcinoma; thyroid nodules

Full Text


References

Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807-20810

Kovacs RB, Földes J, Winkler G, Bodo M, Sapi Z. The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol 2003; 149: 449-453

Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004; 9: 305-28.

Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 2008; 132: 359-372

Orlandi F, E Saggiorato, G Pivano, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A. Galectin-3 as a presurgical marker of human thyroid carcinoma. Cancer Research 1998; 58: 3015-3020

Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. The Lancet Oncology 2008; 9: 543-549

Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002; 126: 710-713.

Lin HM, Moon B, Yu F, KimHR. Galectin-3 mediates geninstein-induced G2/M arrest and inhibits apoptosis. Carcinogenesis 2000; 21: 1941-1945

Yang RY, Hsu DK, Liu FT. Expression of Galectin-3 modulates T-cell growth and apoptosis. Immunology 1996; 93: 6737-6742

Inohara H, Akahani S, Koths K, Raz A. Interactions between Galectin-3 and Mac-2 binding protein mediate cell-cell adhesion. Cancer Research 1996; 56: 4530-4534

Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998; 83:2638-2648.

Grodski S, Delbridge L. An update on papillary microcarcinoma. Curr Opin Oncol 2008; 21: 1-4

Bomeli SR, LeBeau SO, Ferris RL. Evaluation of a thyroid nodule. Otolaryngol Clin North Am 2010; 43: 229-238

Papotti M, Volante M, Saggiorato E, Deandreis D, Veltri A, Orlandi F. Role of Galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. Eur J Endocrinol 2001; 147: 515-521

Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001; 14: 338-342

Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M. Thyroid peroxidase and Galectin-3 immunostaining in differentiated thyroid carcinoma: diagnostic usefulness and clinicopathological correlation. Hum Pathol 2008; 39: 1656-1663

Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clinl Pathol 2002; 117: 143-150

Saggiorato E, Cappia S, Guili P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 5152-5158

Grogan RH, Mitmaker EJ, Clark OH. The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers 2010; 2: 885-912

Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol 2006; 17: 213-223

Zosin I, Cornianu M, Golu I, Balas M. Usefulness of immunohistochemistry in the diagnosis of nodular thyroid disease. Acta Endo (Buc) 2007; 3: 437-450

Saleh HA, Jin B, Barnwell J, Arzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol, 2010; 5:9

Ito Y, Yoshida H, Tomoda C, et al. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology. 2005;37:296-298

Ardito G, Revelli L, Boninsegna A, Sgambato A, Moschella F, Marzola MC, Giustozzi E, Avenia N, Castelli M, Rubello D. Immunohistochemical evaluation of inflammatory and proliferative markers in adjacent normal thyroid tissue in patients undergoing total thyroidectomy: results of a preliminary study. Journal of experimental and clinical cancer research 2010; 17: 29-77

Tatic S. Histopathological and immunohistochemical features of thyroid cancer. Arch Oncol 2003; 11: 173-174

Prasad ML, Pellegata NS, Huang Y, Nagaraja NH, Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Modern Pathology 2005; 18: 48-57

Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.Endocr Pathol 2005; 16: 295-309

Coli A, Bigotti G, Zucchetti F, Negro F, Massi F. Galectin-3, a marker of well-diffentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002; 40: 80-87

Siderova M, Hristozov K, Krasnaliev I, Softova E, Boeva E. Application of immunohistochemical markers in the differential diagnosis of thyroid tumors. Acta Endocrinologica, 2013, 9: 41-52




DOI: http://dx.doi.org/10.14748/ssm.v48i3.1739

Refbacks

About The Authors

Mira Siderova
Medical University of Varna University Hospital "St. Marina", Varna Clinic of Endocrinology
Bulgaria

Kiril Hristozov
Medical University of Varna University Hospital "St. Marina", Varna Clinic of Endocrinology

Ivan Krasnaliev
Medical University of Varna University Hospital "St. Marina", Varna Department of Pathology

Radoslav Radev
Medical University of Varna University Hospital "St. Marina", Varna Department of Surgery

Rumen Nenkov
Medical University of Varna University Hospital "St. Marina", Varna Department of Surgery

Font Size


|